Results 91 to 100 of about 116,210 (265)

Neutropenia induced by ceftriaxone and meropenem

European Journal of Case Reports in Internal Medicine
Neutropenia by non-chemotherapy drugs is an extremely rare idiosyncratic life-threatening drug reaction. Ceftriaxone and meropenem are widely used broad-spectrum antibiotics and are generally safe and well tolerated.
Zay Yar Aung, Khaled Elmagraby, Alexandra Nica   +2 more
doaj   +1 more source

Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review

Head &Neck, EarlyView.
ABSTRACT Objective To provide a comprehensive review of the biological rationale, clinical evidence, and practical perioperative management of immunotherapy for the head and neck surgeon. Summary Background Data Standard treatment for resectable head and neck squamous cell carcinoma (HNSCC) has reached a survival plateau, with over 50% of patients ...
Nicholas Brian Shannon, Bruce Ashford
wiley   +1 more source

Secondary Neutropenias

Biomedicines
Neutrophils are a critical component of immunity, particularly against bacteria and other pathogens, but also in inflammation and tissue repair. As a consequence, individuals with neutropenia, defined by a reduction in absolute neutrophil counts, exhibit a strong propensity to severe infections that typically present with muted symptoms.
openaire   +3 more sources

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

HAX1 mutation in an infant with severe congenital neutropenia

The Turkish Journal of Pediatrics, 2010
Severe congenital neutropenia (SCN) is a rare primary myelopoiesis disorder, characterized by persistent severe neutropenia and early-onset bacterial infections.
Aziz Eghbali, Peyman Eshghi, Fatemeh Malek, Hengameh Abdollahpour, Nima Rezaei   +4 more
doaj  

Cohen syndrome and neutropenia: Unveiling a novel VPS13B variant and literature review

Pediatrics and Neonatology
Objective: To report a novel VPS13B variant and to describe the prevalence of neutropenia and immunological clinical features in patients with Cohen syndrome (CS).
Gioacchino Andrea Rotulo, Lorenzo Sinibaldi, Elisa Profeti, Ludovica Ricci, Donato Amodio, Stefania Ferradino, Giancarlo Iarossi, Gigliola Di Matteo, Chiara Passarelli, Antonio Novelli, Paolo Palma, Andrea Finocchi   +11 more
doaj   +1 more source

DPYD and UGT1A1 Genotype‐Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant‐Specific Impact on Treatment Intensity and Toxicity

International Journal of Cancer, EarlyView.
Pre‐treatment DPYD and UGT1A1 genotyping is increasingly used to prevent fluoropyrimidine‐ and irinotecan‐related toxicity, but variant‐specific real‐world effects remain unclear. In an unselected cohort of cancer patients with actionable genotypes, genotype‐driven dosing improved safety while preserving treatment exposure in high‐risk DPYD c.1905+1G>A
Martina Gambron, Elena Peruzzi, Samantha Perfler, Marcella Montico, Riccardo Cecchin, Elena De Mattia, Michele Spina, Camilla Lisanti, Serena Corsetti, Luisa Foltran, Fabio Puglisi, Rossana Roncato, Erika Cecchin   +12 more
wiley   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

International Journal of Cancer, EarlyView.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden, Tamara J. Huizer, Ben M. Eyck, Ate van der Gaast, Leni van Doorn, Marjolein Y. V. Homs, J. Jan B. van Lanschot, Joost J. M. E. Nuyttens, Lindsey Oudijk, Manon C. W. Spaander, Bas P. L. Wijnhoven, Bianca Mostert, Sjoerd M. Lagarde   +12 more
wiley   +1 more source

A Single Center Survey of Patients With Congenital Neutropenia: Report From Northwestern Iran

Acta Medica Iranica, 2018
Neutropenia is characterized by a decrease in circulating neutrophil counts and consequent infections.  The present study was performed so as to describe the clinical and laboratory findings of patients with congenital neutropenia in northwestern Iran ...
Mahnaz Sadeghi-Shabestari, Samaneh Dousti, Azim Rezamand, Sara Harsini, Nima Rezaei   +4 more
doaj